retatrutide phase 2 trial type 2 diabetes weight loss 2024 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 Retatrutide, a TRIPLE agonist (GLP1,

and plans to drop a bold ad about the 1% during the Super Bowl

LISTEN | What's going on with peptides?: The FDA, in documents for the meeting, said many of the peptides lack adequate human safety and efficacy data

GIP receptors influence insulin secretion pathways and lipid metabolism

Eli Lillys Phase 3 TRIUMPH-4 trial (December 2025) reported that participants taking 12mg of Retatrutide over 68 weeks lost an average of 28.7% of their body weight, the highest result ever reported at that stage for any obesity-related compound

So, this isnt a manipulative or dishonest approach by Henry

The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: The SURPASS clinical trials